The BN6, BN7, and BN8 peptides are modifications of the BN4, BN2, and BN5 peptides, respectively, in which a DPhe has been introduced at the N-terminus in order to increase binding affinity as previously described [11].
One of these residues is Leu-184 which displays an ∼10-fold increase in EC50 with a conservative Ile substitution, but shows very little change in antagonist binding affinity, as previously reported (9).
The highly conserved basic DNA contact surfaces of Myc2 and Myc1 are very similar in their primary structures (Fig. 4D), and the analysis showed that Myc2 p15 binds to double-stranded DNA containing a consensus Myc binding site almost as efficiently as Myc1 p16 (Fig. 4C), whereas Max p22 displayed lower binding affinity as reported previously (Hartl et al., 2010).
Receptor binding affinities as well as enzyme inhibitory properties of the new compound SLV329 were evaluated in a series of 94 receptors and 6 phosphodiesterases as described previously [29].
In fact modulation of the pharmacophore elements present in bile acids could provide high affinity binding molecules, as previously testified by the development of TGR5 and FXR agonists [34].
The number of receptors and binding affinities were determined as previously described (Obiri et al, 1993; Puri et al, 1991).
Our gain-of-function analysis in the FcγRIIIa oligosaccharide at Asn-162 (N-162) confirmed that N-162 is the element required for the high binding affinity to nonfucosylated antibodies, as previously revealed by loss-of-function analyses.
Our results identified 10 SNPs, which putatively modify the binding affinity of 24 TFs previously identified as related to TB and HIV/AIDS expression profiles (e.g. KLF5, CEBPA and NFKB1 for TB; FOXP2, BRCA1, CEBPB, CREB1, EBF1 and ZNF354C for HIV/AIDS; and RUNX2, HIF1A, JUN/AP-1, NR4A2, EGR1 for both diseases).
This binding affinity serves as one molecular metric of immunogenicity.
The binding affinity of the lipopeptides for purified LPS was examined using our synthetic dansyl-polymyxin binding assay as previously reported.
Biotinylated M1, M2, or M1 + M2 LoNA (mutations on LoNA NCL-binding sites) showed no preferential binding affinity to FBL as compared to WT LoNA (Supplementary Fig. 4c).
